Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.

Cancer Immunol Immunother · 2023 · PMC10198917 · PMID 36690799

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

at the edge of significancep = 0.06so close (0.05 < p ≤ 0.1)

However, it was associated with early-death events at the edge of significance (HR 2.18, p = 0.06).

also in 60 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.